Published in Proc Natl Acad Sci U S A on May 10, 1994
Virus-specific CD4(+) memory-phenotype T cells are abundant in unexposed adults. Immunity (2013) 3.38
Fluorogenic probes for monitoring peptide binding to class II MHC proteins in living cells. Nat Chem Biol (2007) 2.04
Peptide binding specificity of HLA-DR4 molecules: correlation with rheumatoid arthritis association. J Exp Med (1995) 2.02
HLA-DR4-IE chimeric class II transgenic, murine class II-deficient mice are susceptible to experimental allergic encephalomyelitis. J Exp Med (1996) 1.99
Precise prediction of major histocompatibility complex class II-peptide interaction based on peptide side chain scanning. J Exp Med (1994) 1.81
Editing of the HLA-DR-peptide repertoire by HLA-DM. EMBO J (1996) 1.74
Identification of a MHC class II-restricted human gp100 epitope using DR4-IE transgenic mice. J Immunol (2000) 1.66
HLA-DM recognizes the flexible conformation of major histocompatibility complex class II. J Exp Med (2000) 1.56
Identification and modulation of a naturally processed T cell epitope from the diabetes-associated autoantigen human glutamic acid decarboxylase 65 (hGAD65). Proc Natl Acad Sci U S A (2001) 1.17
T-cell, adhesion, and B-cell epitopes of the cell surface Streptococcus mutans protein antigen I/II. Infect Immun (1995) 1.16
Analysis of families at risk for insulin-dependent diabetes mellitus reveals that HLA antigens influence progression to clinical disease. Mol Med (1995) 1.10
Motifs and supermotifs for MHC class II binding peptides. J Exp Med (1995) 0.96
Critical contribution of beta chain residue 57 in peptide binding ability of both HLA-DR and -DQ molecules. Proc Natl Acad Sci U S A (1996) 0.95
Pyrrolinone-based peptidomimetics. "Let the enzyme or receptor be the judge". Acc Chem Res (2010) 0.94
Identification of ricin A-chain HLA class II-restricted epitopes by human T-cell clones. Clin Exp Immunol (2001) 0.94
Permissive recognition of a mycobacterial T-cell epitope: localization of overlapping epitope core sequences recognized in association with multiple major histocompatibility complex class II I-A molecules. Immunology (1995) 0.92
Myelin-reactive type B T cells and T cells specific for low-affinity MHC-binding myelin peptides escape tolerance in HLA-DR transgenic mice. J Immunol (2008) 0.92
High-throughput engineering and analysis of peptide binding to class II MHC. Proc Natl Acad Sci U S A (2010) 0.91
Interaction of MHC class II molecules with the invariant chain: role of the invariant chain (81-90) region. EMBO J (1997) 0.89
HLA-DR: molecular insights and vaccine design. Curr Pharm Des (2009) 0.85
Structure-based design of altered MHC class II-restricted peptide ligands with heterogeneous immunogenicity. J Immunol (2013) 0.85
Hindering auxiliary anchors are potent modulators of peptide binding and selection by I-Ak class II molecules. Proc Natl Acad Sci U S A (2000) 0.84
Second-generation peptidomimetic inhibitors of antigen presentation effectively treat autoimmune diseases in HLA-DR-transgenic mouse models. J Autoimmun (2006) 0.84
H-2-associated effects of flanking residues on the recognition of a permissive mycobacterial T-cell epitope. Immunology (1995) 0.83
Prediction of T-cell epitopes of hepatitis C virus genotype 5a. Virol J (2014) 0.78
Human B cells secrete migration inhibition factor (MIF) and present a naturally processed MIF peptide on HLA-DRB1*0405 by a FXXL motif. Immunology (1999) 0.77
An unstable Th epitope of P. falciparum fosters central memory T cells and anti-CS antibody responses. PLoS One (2014) 0.77
MHC structure and function – antigen presentation. Part 1. Einstein (Sao Paulo) (2015) 0.76
An Approach for a Synthetic CTL Vaccine Design against Zika Flavivirus Using Class I and Class II Epitopes Identified by Computer Modeling. Front Immunol (2017) 0.75
Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. Nature (1991) 13.90
Searching for peptide ligands with an epitope library. Science (1990) 10.75
Three-dimensional structure of the human class II histocompatibility antigen HLA-DR1. Nature (1993) 8.75
Peptides on phage: a vast library of peptides for identifying ligands. Proc Natl Acad Sci U S A (1990) 6.34
Characterization of peptides bound to the class I MHC molecule HLA-A2.1 by mass spectrometry. Science (1992) 5.99
Sequence analysis of peptides bound to MHC class II molecules. Nature (1991) 5.99
Specificity and promiscuity among naturally processed peptides bound to HLA-DR alleles. J Exp Med (1993) 4.99
Random peptide libraries: a source of specific protein binding molecules. Science (1990) 4.88
Crystal structures of two viral peptides in complex with murine MHC class I H-2Kb. Science (1992) 4.74
Predominant naturally processed peptides bound to HLA-DR1 are derived from MHC-related molecules and are heterogeneous in size. Nature (1992) 3.85
The structure of HLA-B27 reveals nonamer self-peptides bound in an extended conformation. Nature (1991) 3.84
Promiscuous and allele-specific anchors in HLA-DR-binding peptides. Cell (1993) 3.41
Peptides presented to the immune system by the murine class II major histocompatibility complex molecule I-Ad. Science (1992) 3.39
Tetanus toxin: primary structure, expression in E. coli, and homology with botulinum toxins. EMBO J (1986) 2.62
On the interaction of promiscuous antigenic peptides with different DR alleles. Identification of common structural motifs. J Immunol (1991) 2.49
Peptide binding to HLA-DR1: a peptide with most residues substituted to alanine retains MHC binding. EMBO J (1990) 2.42
Crystal structure of the major histocompatibility complex class I H-2Kb molecule containing a single viral peptide: implications for peptide binding and T-cell receptor recognition. Proc Natl Acad Sci U S A (1992) 2.16
Identification of a motif for HLA-DR1 binding peptides using M13 display libraries. J Exp Med (1992) 1.78
The primary structure of human cartilage link protein. Nucleic Acids Res (1990) 1.76
Cloning and primary structure of a human islet isoform of glutamic acid decarboxylase from chromosome 10. Proc Natl Acad Sci U S A (1991) 1.74
Selection of T cell epitopes and vaccine engineering. Methods Enzymol (1991) 1.50
The structure of the antigen-binding groove of major histocompatibility complex class I molecules determines specific selection of self-peptides. Proc Natl Acad Sci U S A (1991) 1.47
Conformational and structural characteristics of peptides binding to HLA-DR molecules. J Immunol (1991) 1.22
Peptide binding to soluble HLA-DR4 molecules produced by insect cells. J Immunol (1992) 0.85
Differential expression of chemokine receptors and chemotactic responsiveness of type 1 T helper cells (Th1s) and Th2s. J Exp Med (1998) 8.56
Unique chemotactic response profile and specific expression of chemokine receptors CCR4 and CCR8 by CD4(+)CD25(+) regulatory T cells. J Exp Med (2001) 5.56
Generation of tissue-specific and promiscuous HLA ligand databases using DNA microarrays and virtual HLA class II matrices. Nat Biotechnol (1999) 5.13
Identification of LFA-1 as a candidate autoantigen in treatment-resistant Lyme arthritis. Science (1998) 3.68
Selective expression of an interleukin-12 receptor component by human T helper 1 cells. J Exp Med (1997) 3.57
Promiscuous and allele-specific anchors in HLA-DR-binding peptides. Cell (1993) 3.41
Regulation of human lymphocyte proliferation by a heterodimeric cytokine, IL-12 (cytotoxic lymphocyte maturation factor). J Immunol (1991) 3.40
The traditional and a new version of the mouse H-2 complex. Nature (1981) 3.12
Selective up-regulation of chemokine receptors CCR4 and CCR8 upon activation of polarized human type 2 Th cells. J Immunol (1998) 2.84
Inhibition of IL-12 production by 1,25-dihydroxyvitamin D3. Involvement of NF-kappaB downregulation in transcriptional repression of the p40 gene. J Clin Invest (1998) 2.78
Transcript imaging of the development of human T helper cells using oligonucleotide arrays. Nat Genet (2000) 2.71
The chemokine receptor CCR8 is preferentially expressed in Th2 but not Th1 cells. J Immunol (1998) 2.32
Why peptides? Their possible role in the evolution of MHC-restricted T-cell recognition. Immunol Today (1989) 2.23
Identification and chemical synthesis of a ribosomal protein antigenic determinant in systemic lupus erythematosus. Proc Natl Acad Sci U S A (1986) 2.18
Fractalkine (CX3CL1) as an amplification circuit of polarized Th1 responses. J Clin Invest (2001) 2.10
The C-C chemokine receptors CCR4 and CCR8 identify airway T cells of allergen-challenged atopic asthmatics. J Clin Invest (2001) 2.05
Peptide binding specificity of HLA-DR4 molecules: correlation with rheumatoid arthritis association. J Exp Med (1995) 2.02
HLA-DR4-IE chimeric class II transgenic, murine class II-deficient mice are susceptible to experimental allergic encephalomyelitis. J Exp Med (1996) 1.99
Identification of a CD4 binding site on the beta 2 domain of HLA-DR molecules. Nature (1992) 1.98
Beta2-agonists prevent Th1 development by selective inhibition of interleukin 12. J Clin Invest (1997) 1.94
Mechanisms influencing the immunodominance of T cell determinants. J Exp Med (1988) 1.91
Proteolytic processing of avian sarcoma and leukosis viruses pol-endo recombinant proteins reveals another pol gene domain. J Virol (1987) 1.85
Precise prediction of major histocompatibility complex class II-peptide interaction based on peptide side chain scanning. J Exp Med (1994) 1.81
Identification of a motif for HLA-DR1 binding peptides using M13 display libraries. J Exp Med (1992) 1.78
Immune response gene control of determinant selection. III. Polypeptide fragments of insulin are differentially recognized by T but not by B cells in insulin immune guinea pigs. J Immunol (1981) 1.71
Intramolecular dislocation of the COOH terminus of the lac carrier protein in reconstituted proteoliposomes. Proc Natl Acad Sci U S A (1984) 1.68
Cytotoxic T cells specific for glutamic acid decarboxylase in autoimmune diabetes. J Exp Med (1995) 1.67
In vivo competition between self peptides and foreign antigens in T-cell activation. Nature (1988) 1.66
The role of Stat4 in species-specific regulation of Th cell development by type I IFNs. J Immunol (1998) 1.65
Genetics of the major histocompatibility complex: the final act. Annu Rev Immunol (1983) 1.65
Isolation and characterization of Ni-specific T cell clones from patients with Ni-contact dermatitis. J Immunol (1985) 1.59
Melanoma cells present a MAGE-3 epitope to CD4(+) cytotoxic T cells in association with histocompatibility leukocyte antigen DR11. J Exp Med (1999) 1.58
The N-terminal domain of RGS4 confers receptor-selective inhibition of G protein signaling. J Biol Chem (1998) 1.51
Inhibition of calcium/calmodulin-dependent protein kinase in Drosophila disrupts behavioral plasticity. Neuron (1993) 1.51
Interaction of an immunodominant epitope with Ia molecules in T-cell activation. Proc Natl Acad Sci U S A (1988) 1.51
Selection of T cell epitopes and vaccine engineering. Methods Enzymol (1991) 1.50
High affinity human IgE receptor (Fc epsilon RI). Analysis of functional domains of the alpha-subunit with monoclonal antibodies. J Biol Chem (1991) 1.49
Responder T cells depleted of alloreactive cells react to antigen presented on allogeneic macrophages from nonresponder strains. J Exp Med (1981) 1.49
Biochemical analysis of the transducin-phosphodiesterase interaction. Nat Struct Biol (1994) 1.46
Assessment of thermal conditions in neonatal care: use of a manikin of premature baby size. Am J Perinatol (1992) 1.45
Protection against malaria in Aotus monkeys immunized with a recombinant blood-stage antigen fused to a universal T-cell epitope: correlation of serum gamma interferon levels with protection. Infect Immun (1992) 1.45
The viral chemokine macrophage inflammatory protein-II is a selective Th2 chemoattractant. Blood (1998) 1.42
Ia antigens as restriction molecules in Ir-gene controlled T-cell proliferation. Immunol Rev (1981) 1.42
M2 delta, a candidate for the structure lining the ionic channel of the nicotinic cholinergic receptor. Proc Natl Acad Sci U S A (1988) 1.42
Synthetic peptides as substrates and inhibitors of a retroviral protease. Proc Natl Acad Sci U S A (1988) 1.41
A novel granulocyte-derived peptide with lipopolysaccharide-neutralizing activity. J Immunol (1994) 1.39
Channel protein engineering: synthetic 22-mer peptide from the primary structure of the voltage-sensitive sodium channel forms ionic channels in lipid bilayers. Proc Natl Acad Sci U S A (1988) 1.35
Induction of regulatory T-lymphocyte responses by liposomes carrying major histocompatibility complex molecules and foreign antigen. Nature (1985) 1.34
Chemokines and their receptors guiding T lymphocyte recruitment in lung inflammation. Am J Respir Crit Care Med (2001) 1.32
Avian retroviral protease and cellular aspartic proteases are distinguished by activities on peptide substrates. J Biol Chem (1989) 1.29
Assessment in humans of a synthetic peptide-based vaccine against the sporozoite stage of the human malaria parasite, Plasmodium falciparum. J Immunol (1988) 1.28
Relationship between peptide selectivities of human transporters associated with antigen processing and HLA class I molecules. J Immunol (1998) 1.28
Pocket 4 of the HLA-DR(alpha,beta 1*0401) molecule is a major determinant of T cells recognition of peptide. J Exp Med (1995) 1.28
Genetic control of T-cell proliferative responses to poly(glu40ala60) and poly(glu51lys34tyr15): subregion-specific inhibition of the responses with monoclonal Ia antibodies. Immunogenetics (1980) 1.27
Competition for antigen presentation in living cells involves exchange of peptides bound by class II MHC molecules. Nature (1989) 1.26
H-2-controlled suppression of T cell response to lactate dehydrogenase B. Characterization of the lactate dehydrogenase B suppressor pathway. J Exp Med (1982) 1.22
Properties of the ribosomal P2 protein autoantigen are similar to those of foreign protein antigens. Proc Natl Acad Sci U S A (1988) 1.22
Localization of Th-cell subsets in inflammation: differential thresholds for extravasation of Th1 and Th2 cells. Immunol Today (2000) 1.21
The circumsporozoite protein gene from NF54, a Plasmodium falciparum isolate used in malaria vaccine trials. Mol Biochem Parasitol (1989) 1.20
Triggering receptor expressed on myeloid cells: role in the diagnosis of lung infections. Eur Respir J (2004) 1.20
The alpha subunit of the human IgE receptor (FcERI) is sufficient for high affinity IgE binding. J Biol Chem (1990) 1.19
Epitopes recognized by human T cells map within the conserved part of the GP190 of P. falciparum. Science (1988) 1.19
Suppression of cell-mediated lymphocytotoxicity against minor histocompatibility antigens mediated by Lyt-1+Lyt-2+ T cells of stimulator-strain origin. Eur J Immunol (1982) 1.19
HLA polymorphism and T cell recognition of a conserved region of p190, a malaria vaccine candidate. Int Immunol (1991) 1.16
An immunochemical analysis of the distribution of a brain-specific polypeptide, PEP-19. J Neurochem (1988) 1.16
Molecular characterization of interleukin 12. Arch Biochem Biophys (1992) 1.15
Antibodies to the IL-12 receptor beta 2 chain mark human Th1 but not Th2 cells in vitro and in vivo. J Immunol (1999) 1.15
Peptide competition for antigen presentation. Immunol Today (1990) 1.14
Plasmodium falciparum-specific human T cell clones: evidence for helper and cytotoxic activities. Eur J Immunol (1987) 1.14
Isolation and sequencing of two cerebellum-specific peptides. Proc Natl Acad Sci U S A (1984) 1.12
Cytotoxic monoclonal antibody specific for the Lyt-1.2 antigen. Immunogenetics (1982) 1.12
Absence of Ir gene control of T cells recognizing foreign antigen in the context of allogenic MHC molecules. Nature (1982) 1.10
Residual type 1 immunity in patients genetically deficient for interleukin 12 receptor beta1 (IL-12Rbeta1): evidence for an IL-12Rbeta1-independent pathway of IL-12 responsiveness in human T cells. J Exp Med (2000) 1.09
Structural requirements for the interaction between peptide antigens and I-Ed molecules. J Immunol (1989) 1.09
CD4+ T cell clones obtained from Plasmodium falciparum sporozoite-immunized volunteers recognize polymorphic sequences of the circumsporozoite protein. J Immunol (1993) 1.09
A novel type of T-T cell interaction removes the requirement for I-B region in the H-2 complex. Proc Natl Acad Sci U S A (1981) 1.08
Camstatins are peptide antagonists of calmodulin based upon a conserved structural motif in PEP-19, neurogranin, and neuromodulin. J Biol Chem (1996) 1.07
Biochemical and functional analysis of soluble human interleukin-2 receptor produced in rodent cells. Solid-phase reconstitution of a receptor-ligand binding reaction. J Biol Chem (1987) 1.06
Inhibition by IL-12 and IFN-alpha of I-309 and macrophage-derived chemokine production upon TCR triggering of human Th1 cells. Eur J Immunol (2000) 1.05
Pharmacological characterization of the novel nonpeptide orphanin FQ/nociceptin receptor agonist Ro 64-6198: rapid and reversible desensitization of the ORL1 receptor in vitro and lack of tolerance in vivo. J Pharmacol Exp Ther (2001) 1.05
Selective interaction of Ni with an MHC-bound peptide. EMBO J (1991) 1.03
HLA class II peptide binding specificity and autoimmunity. Adv Immunol (1997) 1.02
The treatment of acute hemorrhagic pancreatitis by sump drainage. Surg Gynecol Obstet (1968) 1.02
Analysis of the permissive association of a malaria T cell epitope with DR molecules. J Immunol (1991) 1.01
Lyt phenotypes of primary cytotoxic T cells generated across the A and E region of the H-2 complex. Eur J Immunol (1981) 1.00
Pathogenesis and immunotherapy of autoimmune diseases. Immunol Today (1997) 1.00
Platelet activation by von Willebrand factor requires coordinated signaling through thromboxane A2 and Fc gamma IIA receptor. J Biol Chem (2001) 1.00
Upregulation of integrin alpha6/beta1 and chemokine receptor CCR1 by interleukin-12 promotes the migration of human type 1 helper T cells. Blood (1999) 0.99
Selection of H-2 molecules for the context of antigen recognition by T lymphocytes. Immunogenetics (1981) 0.98
Diacylglycerol kinase-alpha phosphorylation by Src on Y335 is required for activation, membrane recruitment and Hgf-induced cell motility. Oncogene (2007) 0.98
Structures that delineate orphanin FQ and dynorphin A pharmacological selectivities. J Biol Chem (1998) 0.98
Mhc restriction and Ir genes. Adv Cancer Res (1982) 0.97
Preparation of monoclonal antibodies and site-directed polyclonal antibodies against the lac permease of Escherichia coli. Methods Enzymol (1986) 0.97